Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716885 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KCNH2KDM4EGAAHDAC3 | |
| Tetramethylammonium Ion SCHEMBL1130159 | 0.94 | KCNH2 (0.41) | SMN1; SMN2KCNH2KDM4EGAA | |
| SCHEMBL8757415 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2KCNH2KDM4EGAAHDAC3 | |
| Tetrabuthylammonium SCHEMBL1130800 | 0.91 | KCNH2 (0.50) | SMN1; SMN2KCNH2KDM4EGAAALDH1A1 | |
| Biphenyl SCHEMBL7784630 | 0.90 | CYP1A2 (0.44) | SMN1; SMN2KCNH2KDM4EGAA | |
| SCHEMBL1131201 | 0.86 | SMN1; SMN2 (0.36) | SMN1; SMN2KCNH2KDM4EGAAALDH1A1 | |
| SCHEMBL1130143 | 0.86 | KCNH2 (0.33) | SMN1; SMN2KCNH2KDM4EGAA | |
| SCHEMBL1130325 | 0.82 | DNM1 (0.47) | SMN1; SMN2KCNH2KDM4EALDH1A1 | |
| SCHEMBL8571110 | 0.82 | HTT (0.44) | KCNH2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL8574920 | 0.82 | HTT (0.44) | KCNH2ALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10001703-B2 | Photopolymer formulation for production of holographic media comprising borates with low TG | COVESTRO DEUTSCHLAND AG (DE) | 2018-06-19 | — | — | US | disclosed |
| US-10001703-B2 | Photopolymer formulation for production of holographic media comprising borates with low TG | COVESTRO DEUTSCHLAND AG (DE) | 2018-06-19 | — | — | US | disclosed |
| EP-3058423-B1 | PHOTOPOLYMER FORMULATION FOR PRODUCING HOLOGRAPHIC MEDIA WITH LOW TG BORATES | COVESTRO DEUTSCHLAND AG (DE) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10001703-B2 | Photopolymer formulation for production of holographic media comprising borates with low TG | PTGIS, TST, MACF1 | SMN1; SMN2 4704/4885KCNH2 3488/4885KDM4E 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.